Table 1.

Examples of deregulated ncRNAs in relationship with their potential as biomarkers in various lymphoma types.

Lymphoma	miRNA	Biomarker Type	Sample Source	Cohort Size		P-value	Reference
				Cases	Controls
DLBCL	miR-155miR-210 miR-21	D	Serum	60	43	0.009 0.02 0.04	[94]
	miR-21	D, P	Serum	62	50	< 0.001	[106]
	miR-15a, miR-16-1, miR-29c, miR-34a, miR-155	D	Serum	75	77	< 0.05	[96]
	miR-155	PR	Biopsy	79	-	0.0008	[102]
	miR-18a miR-181a miR-222	P	Biopsy	176	-	0.038 0.026 0.004	[101]
	SNORA48, miR-106b*, miR-106b, miR-1181, miR-124, miR-1299, miR-25*, miR-33b*, miR-432, miR-551b*, miR-629, miR-652, miR-654-3p, miR-671-5p, miR-766, miR-877*, miR-93, miR-93*	PR	Biopsy	116	-	0.03	[107]
FL	miR-9, miR-9*, miR-301, miR-338, miR-213	D	Biopsy	46	7	NA	[52]
	miR-223, miR-217, miR-222, miR-221, let-7i, let-7b	P	Biopsy	7	11	< 0.05	[53]
MCL	miR-29	P	Biopsy	30	-	0.04	[58a]
HL	miR-494, miR-1973, miR-21	D	Plasma	42	20	0.004 0.007 < 0.0001	[99]
	miR-135a	P	Biopsy	89	-	0.04	[66]
	miR-21, miR-30e, miR-30d, miR-92b	P, PR	Biopsy	29	-	< 0.001	[108]
MALT	miR-150, miR-550, miR-124a, miR-518b, miR-539	D	Biopsy	NA	NA	< 0.001	[71]
SzS	miR-150, miR-191, miR-15a, miR-16	D	PBMCs	36	12	0.04	[109]
	miR-21 miR-214 miR-486	P	PBMCs	23	-	0.03 0.004 0.0038	[75b]
MF	miR-155 miR-92a miR-93	D	Biopsy	19	12	0.014 0.001 0.001	[77]
NK/T-cell	miR-221	D, P	Plasma	79	37	0.038	[100]

ncRNA, non-coding RNA; miR, microRNA; SNOR, small nucleolar RNAs; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle-cell lymphoma; HL, Hodgkin lymphoma; MALT, mucosa-associated lymphoid tissue lymphoma; SzS, Sézary syndrome; MF, mycosis fungoides; NK/T-cell, extra-nodal natural killer T-Cell (NK/T-cell) lymphoma; D, Diagnostic Biomarker; P, prognostic Biomarker; PR, Predictive of response to treatment Biomarker; MV, microvesicles; PBMCs, peripheral blood monuclear cells; NA, not available.